TFF PHARMACEUTICALS, INC.: 10-Q filed 2023-11-14

Name: TFF PHARMACEUTICALS, INC.: 10-Q filed 2023-11-14
Creator: TFF PHARMACEUTICALS, INC.

What TFF PHARMACEUTICALS, INC. reported in its quarterly report filed 2023-11-14 (fiscal Q3 2023): 36 published measures, 109 facts as tagged in accession 0001213900-23-086896.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-14
Fiscal period: fiscal Q3 2023
Accession: 0001213900-23-086896 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TFF PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	14,885,171	USD
At 2022-12-31	24,120,215	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	1,194,242	USD
At 2022-12-31	1,240,756	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	13,690,929	USD
At 2023-06-30	12,282,042	USD
At 2023-03-31	16,543,324	USD
At 2022-12-31	22,879,459	USD
At 2022-09-30	18,022,526	USD
At 2022-06-30	23,939,500	USD
At 2022-03-31	31,585,993	USD
At 2021-12-31	38,737,059	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	9,725,755	USD
At 2022-12-31	16,612,315	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-4,409,244	USD	92
2023-01-01 to 2023-09-30	-16,480,817	USD	273
2023-04-01 to 2023-06-30	-5,020,206	USD	91
2023-01-01 to 2023-03-31	-7,051,367	USD	90
2022-07-01 to 2022-09-30	-7,274,501	USD	92
2022-01-01 to 2022-09-30	-24,396,828	USD	273
2022-04-01 to 2022-06-30	-8,746,325	USD	91
2022-01-01 to 2022-03-31	-8,376,002	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-11,824,588	USD	273
2022-01-01 to 2022-09-30	-19,640,198	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	48,359	USD	273
2022-01-01 to 2022-09-30	1,410,159	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	234,763	USD	92
2023-01-01 to 2023-09-30	619,543	USD	273
2022-07-01 to 2022-09-30	87,586	USD	92
2022-01-01 to 2022-09-30	183,025	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	5,012,845	USD	273
2022-01-01 to 2022-09-30	414,740	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-48,359	USD	273
2022-01-01 to 2022-09-30	-1,410,159	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-113,569,239	USD
At 2022-12-31	-97,088,422	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	47,441,693	shares	92
2023-01-01 to 2023-09-30	39,983,825	shares	273
2022-07-01 to 2022-09-30	25,451,691	shares	92
2022-01-01 to 2022-09-30	25,399,352	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	47,441,693	shares	92
2023-01-01 to 2023-09-30	39,983,825	shares	273
2022-07-01 to 2022-09-30	25,451,691	shares	92
2022-01-01 to 2022-09-30	25,399,352	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.09	USD/shares	92
2023-01-01 to 2023-09-30	-0.41	USD/shares	273
2022-07-01 to 2022-09-30	-0.29	USD/shares	92
2022-01-01 to 2022-09-30	-0.96	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-0.09	USD/shares	92
2023-01-01 to 2023-09-30	-0.41	USD/shares	273
2022-07-01 to 2022-09-30	-0.29	USD/shares	92
2022-01-01 to 2022-09-30	-0.96	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-09-30	2,064,354	USD
At 2022-12-31	3,078,342	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	2,343,859	USD	273
2022-01-01 to 2022-09-30	3,328,344	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-4,420,600	USD	92
2023-01-01 to 2023-09-30	-16,525,956	USD	273
2022-07-01 to 2022-09-30	-7,280,620	USD	92
2022-01-01 to 2022-09-30	-24,416,012	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	10,892,899	USD
At 2022-12-31	19,025,166	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	1,142,012	USD
At 2022-12-31	1,130,662	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	983,287	USD
At 2022-12-31	919,607	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	4,655,363	USD	92
2023-01-01 to 2023-09-30	17,145,499	USD	273
2022-07-01 to 2022-09-30	7,368,206	USD	92
2022-01-01 to 2022-09-30	24,599,037	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,386,707	USD	92
2023-01-01 to 2023-09-30	9,087,264	USD	273
2022-07-01 to 2022-09-30	4,025,940	USD	92
2022-01-01 to 2022-09-30	14,360,293	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	59,133,574	shares
At 2022-12-31	36,193,085	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	9,725,755	USD
At 2022-12-31	16,612,315	USD
At 2022-09-30	13,147,090	USD
At 2021-12-31	33,794,672	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-09-30	-203,712	USD
At 2022-12-31	-139,295	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2023-09-30	139,230	USD
At 2022-12-31	196,044	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2023-09-30	134,955	USD
At 2022-12-31	190,719	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2023-09-30	7,688	USD
At 2022-12-31	7,688	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-09-30	805,659	USD
At 2022-12-31	2,226,344	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-4,447,426	USD	92
2023-01-01 to 2023-09-30	-16,545,234	USD	273
2022-07-01 to 2022-09-30	-7,377,727	USD	92
2022-01-01 to 2022-09-30	-24,558,254	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	2,268,656	USD	92
2023-01-01 to 2023-09-30	8,058,235	USD	273
2022-07-01 to 2022-09-30	3,342,266	USD	92
2022-01-01 to 2022-09-30	10,238,744	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	371,814	USD	273
2022-01-01 to 2022-09-30	267,311	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	11,356	USD	92
2023-01-01 to 2023-09-30	45,139	USD	273
2022-07-01 to 2022-09-30	6,119	USD	92
2022-01-01 to 2022-09-30	19,184	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	25,000	USD	92
2023-01-01 to 2023-09-30	25,272	USD	273
2022-01-01 to 2022-09-30	404,555	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	66,910	USD	273
2022-01-01 to 2022-09-30	148,657	USD	273

Inspect the source

Entity: TFF PHARMACEUTICALS, INC. / CIK 0001733413
Captured: 2026-09-21T17:25:24.015Z
SEC response SHA-256: 831f4629fefc666a0d697443131c6e51c7c7a82a58f012a492b81a69560d76f0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001733413.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))